Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
PER Pulse™ Recaps
for Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™ focuses on a series of video interviews with leading experts in immunotherapy for cancer that are featured in an online CME activity currently available at www.gotoper.com
Release Date: December 13, 2016
Expiration Date: December 13, 2017
Media: Internet - based
This activity focuses on immunotherapies in melanoma, non–small cell lung cancer, and gastric cancer; it consists of a series of brief video interviews of leading and short summaries of clinical data related to issues discussed in the interviews. The content and videos are based on presentations given at the 1st Annual European Congress on Immunotherapies in Cancer™, held September 2016 in Barcelona, Spain. The program is designed for community oncologists and addresses currents standards of care and emerging concepts in cancer immunotherapy.
CME/CE Activity Table of Contents
In order to receive a CME/CE certificate, participants must view any number of the modules, complete the posttest with a passing score of 70% or higher, complete the evaluation, and request credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This educational activity is directed toward medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.
At the conclusion of this activity, participants should be better prepared to:
Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, New York, USA
Disclosure: Grant/Research Support: National Cancer Institute; Consultant: AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Eli Lilly, Adgero; Shareholder: Adgero.
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA
Disclosure: Consultant: Merck Sharp & Dohme, Novartis, Roche; Shareholder: Abraxis, CytomX, Compugen, Five Prime, Kite Pharma.
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Vall d' Hebron University Hospital
Vall d'Hebron Institute of Oncology (V.H.I.O.)
Disclosure: Consultant: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, Merck Sharp & Dohme, Merck Serono, Novartis, Roche, Sanofi, Symphogen, Takeda, and Taiho.
It is the policy of Physicians’ Education Resource®, LLC (PER®), to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Physicians’ Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
Minimum System Requirements (Mac OS)
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018